All Clinical Trials:
Oncology Clinical Trial: WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Clinical Trial Protocol # ADVL1217 | Brain Tumor/Central Nervous System/Neuro-Oncology | Contact (714) 509-8646
Oncology Clinical Trials Pilot Project: Harnessing big data for new ideas in pediatric, adolescent and young adult oncology
Clinical Trial Protocol # 160778 | Adolescents and Young Adults, oncology | Contact (714) 509-8646
Phase 1 Study of ABI-009 (nab-rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
Clinical Trial Protocol # ADVL1514 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS
Clinical Trial Protocol # ADVL1711 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Clinical Trial Protocol # ADVL1614 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Clinical Trial Protocol # ADVL1622 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High Grade Glioma (HGG)
Clinical Trial Protocol # CDRB436G2201 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
RXDX-101-03 – A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions (Igny
Clinical Trial Protocol # RXDX 101 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646
TINI, Total Therapy For Infants with Acute Lymphoblastic Leukemia (ALL) I
Clinical Trial Protocol # TINI | Leukemia | Contact (714) 509-8646
AALL15P1 A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A Gene Rearrangement.
Clinical Trial Protocol # AALL15P1 | Leukemia | Contact (714) 509-8646
ACNS1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Clinical Trial Protocol # ACNS1422 | Brain Tumor/Central Nervous System/Neuro-Oncology | Contact (714) 509-8646
ADVL1521 A Phase 2 Study of the MEK inhibitor Trametinib (IND#119346, NSC#763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Clinical Trial Protocol # ADVL1521 | Leukemia | Contact (714) 509-8646
AHEP1531, Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Clinical Trial Protocol # AHEP1531 | Solid Tumors | Contact (714) 509-8646
Testicular Tissue Cryopreservation for Fertility Preservation in Patients Facing Infertility-causing Diseases or Treatment Regimens
Clinical Trial Protocol - Testicular Cryopreservation | Contact (714) 509-8646
